Form 4: GoodRx Director Converts Deferred Stock Units

GoodRx Holdings Director Ronald E Bruehlman acquired 21,691 shares of Class A Common Stock through the conversion of deferred stock units.

Summary

• Ronald E Bruehlman, a Director of GoodRx Holdings, Inc. (GDRX), reported a transaction on November 8, 2025.
• The transaction involved the conversion of 21,691 deferred stock units (DSUs) into Class A Common Stock.
• Following this transaction, Bruehlman directly beneficially owns 111,025 shares of Class A Common Stock.
• The converted DSUs were part of an award that vested as to one-third of the shares on November 8, 2025.
• Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
• Bruehlman still beneficially owns 43,384 derivative securities (deferred stock units) after this transaction.

Sentiment

Score: 5

Explanation: This is a routine insider transaction report (Form 4) detailing the conversion of deferred stock units. It does not contain information that would significantly alter the company's financial outlook or operational performance, thus maintaining a neutral sentiment.

Positives

• Increased direct beneficial ownership of Class A Common Stock by a director, indicating continued alignment with shareholder interests.
• The vesting and conversion of deferred stock units represent a planned compensation event for the director.

Future Outlook

The remaining deferred stock units will settle on the earliest of December 31, 2029; separation from service; a change in control; death; or disability, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors.

Industry Context

This filing is a routine disclosure of an insider transaction, common across all publicly traded companies. It reflects a director's equity compensation vesting and conversion, which is a standard practice in executive and director compensation structures within the healthcare technology industry.

Comparison to Industry Standards

• The use of Deferred Stock Units (DSUs) as part of director compensation is a common practice across various industries, including healthcare technology, aligning director incentives with long-term shareholder value.
• The vesting schedule (one-third of the award) is typical for equity compensation plans, often designed to retain directors and executives over several years.
• The settlement conditions for DSUs (e.g., separation from service, change in control) are standard provisions found in deferred compensation plans for directors in comparable companies like Teladoc Health (TDOC) or Amwell (AMWL), ensuring tax efficiency and alignment with corporate events.

Related Party Transactions

• The transaction involves equity compensation for a director, which is a standard related-party transaction disclosed in this context.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively as it aligns the director's interests with shareholders.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• Settlement of the remaining 43,384 deferred stock units upon the earliest occurrence of specified events (December 31, 2029; Separation from Service; Change in Control; death; or Disability).

Key Dates

Keywords

GoodRx Holdings, GDRX, Ronald E Bruehlman, Form 4, Insider Transaction, Deferred Stock Units, DSU Conversion, Class A Common Stock, Director Ownership, Equity Compensation